SKL

Rasili's overall verdict on SKL is withheld due to low data confidence. The company has only one full year of financial history available, and the newest statement is 22 months old — well below the three-year window typically needed to assess trends and durability. Within the pillars that could be scored, health ranks strongest at 75, anchored on an F-Score of 3/3 (all observable signals passed), though interest coverage at 1.8× remains thin. Quality scores 27, held back by a net margin of 2.0% and ROE of 6.3%, which are both subdued; debt-to-equity at 1.50× sits at midpoint. Value pillar scores zero across the board: the P/E of 54.6 and earnings yield of 1.8% stand far below the 364-day T-bill rate of 9.03%, creating a spread of −7.2 percentage points. Dividend pillar also scores zero — no payout in the one year observed. Momentum remains unscored as history began only in July 2026.

SKL trades at 13.65 KES as of 2 November 2026. The earnings yield-to-T-bill gap is the starkest single fact: the company earns just 1.8% per KES of price while risk-free instruments yield 9.03%. Liquidity is thin, with median daily turnover around 129,997 KES and turnover equivalent to only 0.5 basis points of estimated market capitalisation. No dividend has been paid. A fresh annual statement and at least two additional years of comparable results would be required to establish whether current metrics reflect structural weakness or cyclical dislocation.

Automated analysis for information & education. Not investment advice.